GT Biopharma (GTBP) Total Liabilities (2010 - 2026)
GT Biopharma (GTBP) posted quarterly Total Liabilities of $10.0 million for Q1 2026, up 276.07% year-over-year from $2.7 million in Q1 2025, and up 23.32% quarter-over-quarter from $8.1 million in Q4 2025.
GT Biopharma (GTBP) Total Liabilities (2010 - 2026) Analysis & Trends
GT Biopharma (GTBP) has reported Total Liabilities for 17 consecutive years, with $10.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 276.07% year-over-year to $10.0 million; the TTM figure through Mar 2026 stood at $10.0 million (up 276.07% YoY), while the FY2025 annual figure was $8.1 million, up 91.54% from the prior year.
- Total Liabilities grew to $10.0 million in Q1 2026 per GTBP's latest filing, from $8.1 million in the prior quarter.
- Across five years, Total Liabilities topped out at $31.0 million in Q2 2025 and bottomed at $1.3 million in Q3 2025.
- Historically, Total Liabilities has averaged $7.7 million across 5 years, with a median of $6.5 million in 2023.
- Annual changes were most pronounced in 2022 — Total Liabilities tumbled 85.71% — and 2026, when it soared 276.07%.
- GT Biopharma's Total Liabilities stood at $5.0 million in 2022, then surged by 32.61% to $6.6 million in 2023, then slumped by 36.2% to $4.2 million in 2024, then surged by 91.54% to $8.1 million in 2025, then advanced by 23.32% to $10.0 million in 2026.
- Business Quant data shows GTBP's Total Liabilities at $10.0 million in Q1 2026, $8.1 million in Q4 2025, and $1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | GT Biopharma | 8.38 Mn | 8.38 Mn | - | 10.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.00 Mn |
| Dec 31, 2025 | 8.11 Mn |
| Sep 30, 2025 | 1.32 Mn |
| Jun 30, 2025 | 31.04 Mn |
| Mar 31, 2025 | 2.66 Mn |
| Dec 31, 2024 | 4.23 Mn |
| Sep 30, 2024 | 6.76 Mn |
| Mar 31, 2024 | 4.60 Mn |
| Dec 31, 2023 | 6.63 Mn |
| Sep 30, 2023 | 6.14 Mn |
| Jun 30, 2023 | 6.38 Mn |
| Mar 31, 2023 | 7.03 Mn |
| Dec 31, 2022 | 5.00 Mn |
| Sep 30, 2022 | 5.12 Mn |
| Jun 30, 2022 | 8.73 Mn |
| Mar 31, 2022 | 9.65 Mn |
| Dec 31, 2021 | 10.26 Mn |
| Sep 30, 2021 | 35.80 Mn |
| Jun 30, 2021 | 39.57 Mn |
| Mar 31, 2021 | 27.64 Mn |